The importance of quantitative volumetric analysis

For over 20 years, volumetric MR imaging (vMRI) technology has been available in research and clinical environments.Initially, radiology centers developed and used their own imaging parameters and manually evaluated the resulting images. This made clinical application subjective, inconsistent from patient to patient and from scanner to scanner,and all but impractical. The introduction of large-scale multi-institutional research studies, such as ADNI (Alzheimer’s Disease Neuroimaging Initiative) in 2004, initiated the streamlining and standardizing of acquisition protocols. In 2006, CorTechs Labs introduced NeuroQuant, the first FDA cleared automated segmentation software, which provided consistent, operator independent measurements of brain structure volumes. Together, these factors permitted clinical users to easily incorporate volumetric MRI technology into their clinical practice.


More Resources

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation
Scroll to Top